Assetmark Inc. Sells 10,459 Shares of Globus Medical, Inc. $GMED

Assetmark Inc. reduced its position in Globus Medical, Inc. (NYSE:GMED) by 88.8% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 1,314 shares of the medical device company’s stock after selling 10,459 shares during the period. Assetmark Inc.’s holdings in Globus Medical were worth $75,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in GMED. Wealth Enhancement Advisory Services LLC boosted its holdings in Globus Medical by 2.8% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 6,316 shares of the medical device company’s stock valued at $375,000 after acquiring an additional 170 shares during the last quarter. GAMMA Investing LLC lifted its position in Globus Medical by 14.7% during the 3rd quarter. GAMMA Investing LLC now owns 1,438 shares of the medical device company’s stock valued at $82,000 after purchasing an additional 184 shares during the period. EverSource Wealth Advisors LLC lifted its position in Globus Medical by 74.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 197 shares during the period. Probity Advisors Inc. boosted its stake in shares of Globus Medical by 5.5% in the 3rd quarter. Probity Advisors Inc. now owns 3,792 shares of the medical device company’s stock valued at $217,000 after purchasing an additional 199 shares during the last quarter. Finally, Ensign Peak Advisors Inc grew its position in shares of Globus Medical by 0.3% during the 2nd quarter. Ensign Peak Advisors Inc now owns 68,468 shares of the medical device company’s stock worth $4,041,000 after buying an additional 230 shares during the period. Institutional investors and hedge funds own 95.16% of the company’s stock.

Globus Medical Price Performance

NYSE GMED opened at $92.01 on Wednesday. Globus Medical, Inc. has a one year low of $51.79 and a one year high of $101.40. The firm has a market cap of $12.31 billion, a P/E ratio of 29.68, a P/E/G ratio of 1.43 and a beta of 1.06. The stock’s 50-day moving average is $90.10 and its 200-day moving average is $75.84.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Tuesday, February 24th. The medical device company reported $1.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.06 by $0.22. The business had revenue of $826.42 million during the quarter, compared to analyst estimates of $803.29 million. Globus Medical had a return on equity of 11.52% and a net margin of 15.30%.Globus Medical’s quarterly revenue was up 25.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.84 EPS. Equities analysts anticipate that Globus Medical, Inc. will post 3.44 EPS for the current year.

Wall Street Analyst Weigh In

GMED has been the subject of a number of recent research reports. Needham & Company LLC raised shares of Globus Medical from a “hold” rating to a “buy” rating and set a $112.00 price target for the company in a research note on Friday, January 30th. BTIG Research reiterated a “neutral” rating on shares of Globus Medical in a research report on Tuesday, December 30th. Barclays increased their price target on Globus Medical from $106.00 to $114.00 and gave the company an “overweight” rating in a research note on Monday, November 10th. TD Cowen raised Globus Medical to a “strong-buy” rating in a research note on Tuesday, January 27th. Finally, Morgan Stanley increased their target price on Globus Medical from $70.00 to $100.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $100.18.

Insider Transactions at Globus Medical

In related news, Director Leslie V. Norwalk sold 2,000 shares of the firm’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $101.10, for a total transaction of $202,200.00. Following the sale, the director directly owned 10,419 shares in the company, valued at $1,053,360.90. This trade represents a 16.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Kyle Kline sold 3,594 shares of the business’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $101.10, for a total transaction of $363,353.40. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 34,136 shares of company stock valued at $3,111,033 over the last quarter. Corporate insiders own 18.54% of the company’s stock.

Key Globus Medical News

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Q4 revenue and adjusted results beat expectations — Globus reported Q4 net sales of $826.4M (+25.7% YoY) and strong adjusted EBITDA/non‑GAAP EPS, driven in part by the Nevro contribution and base business strength. GlobeNewswire Release
• Positive Sentiment: Raised non‑GAAP EPS guidance for 2026 and reconfirmed revenue range — management updated 2026 non‑GAAP EPS to $4.40–$4.50 and reaffirmed revenue of $3.18–$3.22B, signalling confidence in integration and margin leverage. Guidance / Release
• Positive Sentiment: Profitability expansion — company posted record non‑GAAP EPS and sizable increases in gross profit and operating profit, reflecting synergies from acquisitions and cost discipline. Quiver Quant Summary
• Neutral Sentiment: Investor materials and call scheduled — management held a conference call and published detailed GAAP/non‑GAAP reconciliations; listen/transcript available for further color on sustainability of margins. Press Release / Call Materials
• Neutral Sentiment: Wide analyst interest and price‑target dispersion — multiple firms maintain buy/overweight ratings with median targets near $100, but targets vary, so consensus reaction may diverge. Quiver – Analyst Snapshot
• Negative Sentiment: GAAP vs non‑GAAP earnings confusion — GAAP diluted EPS was $1.03 while non‑GAAP EPS was $1.28; some outlets reported an EPS “miss” on GAAP or different consensus metrics, creating headline risk and mixed press coverage. Quiver – EPS Detail
• Negative Sentiment: Growth concentrated in recent acquisitions — base business (ex‑Nevro) grew only ~5% for the year, raising questions about how much of future upside will rely on further M&A versus organic acceleration. Quiver – Business Mix
• Negative Sentiment: Cash and capital deployment concerns plus insider selling — cash and equivalents fell to ~$526M, capex and acquisitions were sizable, and recent insider sales were noted by data providers, which can pressure sentiment. Quiver – Cash & Insider Activity

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.